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Summary Programmes of education in breast self-examination with specialist clinics for self-referral were
introduced in two health districts around 1980. Combining the results from the two centres showed no
reduction in mortality from breast cancer over the following 10 years but the mortality was low in one of the
centres whilst in the other it was higher than in four geographically separate comparison centres in which there
was similar careful monitoring of breast cancer incidence and mortality. Because this was not a randomised
controlled trial and lacked a uniform treatment protocol, biases may be responsible for the differences
observed, but it is also possible that BSE education with annual reinforcement contributed to the breast cancer
mortality reduction seen in one district. The overall conclusion however is that the value of breast self-
examination remains unproven.
Interest in the UK Trial of Early Detection of Breast Cancer
(TEDBC) has tended to focus on the effects of screening by
mammography but the trial also includes two centres, Not-
tingham and Huddersfield, in which women were encouraged
to practise breast self-examination (BSE). As an attempt to
assess prospectively the effects of BSE encouragement on
breast cancer mortality within a defined population it is
unique.
It was found that, while the two screening centres pre-
sented a very similar pattern of breast cancer mortality, the
two centres offering teaching in BSE were dissimilar. Details
of the method of the trial (UK Trial of Early Detection of
Breast Cancer Group, 1981) and of the effects of screening
and BSE education on breast cancer mortality (UK Trial of
Early Detection of Breast Cancer Group, in press) have
already been published. The purpose of this paper is to
explore the possible explanations for the contrast between the
BSE centres.
Method
Recruitment
At the start of the trial the first cohort of women aged 45 to
64 years was recruited from the lists of all general practi-
tioners serving the different populations. Their date of entry
to the trial was the date on which they were first invited by
letter to a BSE class, between 1979 and 1981. The date of
entry in comparison centres was arbitrarily fixed as January
1st 1980. In Nottingham classes and clinics were held at a
fixed central hospital location whereas in Huddersfield alter-
native local community venues were offered. Non-attenders
in Nottingham were initially sent a further appointment for a
BSE class but only 8% responded and second invitations
were therefore discontinued. In Huddersfield a low atten-
dance rate in the first year led to increased efforts to
influence non-attenders. They were sent two more invitations
at 18 month intervals and these included leaflets on BSE and
details of the self-referral clinics which women could attend
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whether or not they had been to the BSE class. Approxi-
mately half the non-attenders as well as the attenders were
sent calendars annually on which they were asked to record
their monthly BSE examination. Training courses were
organised to encourage community nursing staff to teach
BSE wherever the opportunity might arise. Both centres pub-
licised the programme through local newspapers and by hol-
ding open days.
Classes
At the BSE class a short film was shown, demonstrating a
systematic BSE method, and a talk was given by a specially
trained nurse, health educator or surgeon, but there were no
individual demonstrations or base-line examinations of the
breasts.
Clinics
The open-access clinics provided breast examination by a
specially trained nurse and mammography was performed
provided the patient had not had a mammogram within the
last year. Women might instead choose to consult their GPs
in which case no record was sent to the TEDBC unless the
episode led to biopsy.
Breastpathology and treatment
During the first 7 years information on pathological features
was collected for all breast biopsies and personal and treat-
ment details were extracted from clinical case-notes.
After the fieldwork period information on further breast
cancers was mainly obtained from cancer registrations in the
NHS central registries where records of all the women in the
Trial have been flagged. As cancer registration notification is
incomplete and delayed, analysis of incident cancers is
limited to cases occurring within the first 7 years of trial
entry.
There were differences between the centres in surgical and
pathology practice, a major difference being in the propor-
tion of breast cancer cases where nodal status was assessed,
and the extent of such assessment. Consequently operable
tumours are classified according to the maximum diameter
reported by the pathologist rather than by nodal status.
There was some variation between laboratories on whether
measurements were made on fresh or fixed, or both fixed and
sectioned material.
Deaths
Notifications of deaths and cancer registrations are received
from the NHS Central Registry. The breast cancer deaths
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included in this paper are those in which breast cancer was
recorded as the underlying cause of death on the death
certificate and had been first diagnosed after entry to the
trial. Follow up was censored at 31st December 1989 or
within 10 years of entry to the trial, whichever was earlier.
Deaths from breast cancers diagnosed between 7 and 10
years from entry are included in mortality analysis though
not in the incidence data.
Analysis
Mortality rates were calculated, using woman-years of follow
up as denominator since staggered entry led to variable
length of follow-up (UK Trial of Early Detection of Breast
Cancer Group, in press). Expected rates were calculated
adjusting first for age within 5 year bands and year since trial
entry, and second by multiplying this figure by the pre-trial
breast cancer standardised mortality ratio (SMR) taking the
pooled rate over the previous 10 years for all six centres as
standard. The risk of death in each BSE centre has been
calculated relative to that of the combined comparison cen-
tres. Two-tailed probability-values greater than 0.05 are con-
sidered non-significant.
Results
Attendance at classes and clinics
Attendance at classes was markedly lower in Huddersfield
than in Nottingham and declined with age (Table I). Use of
the special breast clinics was higher in the first year after trial
entry than in subsequent years and was higher in Hud-
dersfield than in Nottingham, especially in later years. It
declined with age.
Benign biopsies and breast cancers
The benign biopsy rate was raised 2.1-fold in Huddersfield
but only 1.2-fold in Nottingham compared with that of the
combined comparison centres. The younger women had the
higher rates, but were less affected by the trial intervention.
In contrast to benign biopsy the incidence of malignancy
tended to rise with age at entry and was slightly lower in
Huddersfield than in Nottingham, presenting a 7% increase
relative to the combined comparison centres vs a 13% in-
crease in Nottingham. Both BSE centres reported increased
detection of tumours less than 21 mm, the rate in Hudders-
field being slightly lower than that in Nottingham.
Neither BSE centre experienced much fall in the incidence
of cancers over 20 mm or with fixation or distant metastasis
(Figure 1). Huddersfield, with a slightly raised rate in the
early years which later 'crossed over' that of the comparison
centres, follows the expected pattern for a successful early
detection programme (Day et al., 1989). There was no such
cross-over pattern in Nottingham but the cumulative rate
was lower throughout.
Treatment
Breast conserving operations and the use of hormone therapy
became increasingly popular over the period of the trial.
Chemotherapy, as an adjuvant for early stage disease, was
however little used other than in Huddersfield. Table II
shows that Huddersfield was not only outstanding in the use
made of chemotherapy (in the form of short course mono-
chemotherapy or perioperative poly-chemotherapy) but also
made greater use of breast conserving operations and hor-
mone therapy (tamoxifen). Nottingham used relatively little
of any of these forms of treatment or of radiotherapy.
Mortality
Mortality in the combined BSE centres is the same as in the
combined comparison centres but there are marked
differences between the two BSE centres (Table III). The
relative risk in Huddersfield, adjusted for age and period, is
0.80 and is only slightly affected by further adjustment for
pre-trial differences in breast cancer mortality between the
centres. The relative risk in Nottingham is 1.23 but is
reduced to 1.14 by pre-trial SMR adjustment as the breast
cancer mortality was relatively high in 1969-78. The
difference between Huddersfield and Nottingham, without
pre-trial adjustment, is statistically significant (P <.05), while
those between the comparison centres are not.
Mortality was consistently lower in attenders than in non-
attenders but in Huddersfield both groups had low rates,
whereas in Nottingham they both had high rates (Table IV),
Discussion
The first question to consider is whether the mortality
difference between Huddersfield and Nottingham could be
Table I Class attendance, clinic utilisation, benign biopsy and cancer detection in relation
(percentages of women)
to age at entry
Breast
Class Clinic Clinic Benign cancer
Women attendance attendance attendance biopsy detection
total in Yr I in Yr I in Yrs 2-7 in Yrs 1-7 in Yrs -7
45-49 years
Huddersfield 5040 34.5% 2.6% 7.4% 2.30% 1.31%
Nottingham 11144 56.3% 2.3% 3.5% 1.18% 1.16%
Comparison centres 31553 - - - 1.20% 1.08%
50-54 years
Huddersfield 5866 33.4% 2.5% 5.1% 1.50% 1.16%
Nottingham 10476 54.4% 1.7% 2.4% 0.59% 1.35%
Comparison centres 32138 - - - 0.58% 1.14%
55-59 years
Huddersfield 6423 31.7% 1.8% 4.5% 0.75% 1.42%
Nottingham 10933 52.8% 1.7% 1.7% 0.58% 1.49%
Comparison centres 35644 - - - 0.34% 1.31%
60-64 years
Huddersfield 5253 26.1% 1.3% 2.8% 0.72% 1.22%
Nottingham 8436 48.0% 1.1% 1.0% 0.40% 1.45%
Comparison centres 26742 - - - 0.30% 1.27%
Total
Huddersfield 22582 31.4% 2.1% 4.9% 1.28% 1.28%
Nottingham 40989 53.1% 1.7% 2.2% 0.71% 1.35%
Comparison centres 126077 - - - 0.61% 1.20%210 R. ELLMAN et al.
-a- Huddersfield
* x- Nottingham
- -o Comp. centres
Table IV Age/period adjusted breast cancer mortality rates over
first 10 years in those who attended BSE education in the first year
and those who did not
Deaths in Deaths in
attenders non-attenders
Per 1000 Per 1000
No. w.y. No. w.y.
Huddersfield 20 3.03 71 4.49
Nottingham 108 5.74 124 7.39
Comparison centres 646 5.18
2 _ @.' mortality in Huddersfield but the different measuring
A.9/ methods may invalidate comparisons. The direction of bias is
uncertain; though fixation results in shrinkage, examination
o under the microscope may reveal that infiltration by tumour
0 1 2 3 4 5 6 7 8 is more extensive than is apparent to the naked eye.
Year in trial The fact that Nottingham had a greater increase in breast
cancer incidence than Huddersfield and the small size of
I Cumulative incidence rates for tumours of size these increases relative to the 41-51% increase observed in
.i or with fixation or distant metastasis. the screening centres might be considered to rule out the
possibility that the mortality reduction in Huddersfield is due
ifferences in their BSE programmes. The program- to the early detection programme. However it can be argued
basically similar and it was Nottingham which that success may be critically dependent on the stage at
the higher invitation response rate. However, which the faster growing cancers are picked up and that
ould be influenced by the programme without atten- breast awareness and prompt self-referral by women who
attendance may be a poor guide to whether women develop early signs of cancer may be important. A long lead
BSE satisfactorily and whether, having discovered a time afforded to slow growing cancers, may raise detection
sign, they refer themselves promptly for investiga- rates considerably, but be less critical.
Artefacts of the study design must next be considered. In
ow from an interview survey (Calnan et al., 1983) both centres publicity about the BSE programme could reach
Nottingham 28% of women were practising BSE women before they were personally invited to attend, so that
trily shortly before they were invited to participate, some cancers diagnosed early as a result of the programme
a year later BSE practice among those who attended may have been excluded as 'pre-trial' cases. If such women
had increased to 47% whereas in non-attenders it approached the Trial unit they were permitted to attend but
at 33%. Over the same period practice increased were excluded from analysis. In Nottingham three such
Yo to 28% in a comparison centre. Unfortunately women who attended before invitation and who died of
iformation is not available for Huddersfield or for breast cancer have been excluded, but no such deaths occur-
rs. The greater use made of self-referral clinics in red in Huddersfield. Those who consulted their GP as a
jeld in the later trial years may be an indication that result of publicity are not individually distinguishable.
ield achieved a more sustained level of BSE aware- The inclusion of all pre-trial cases diagnosed within 12
tugh the issue of calendars than could be achieved months of date of entry brings the crude breast cancer
media publicity. mortality risk in Huddersfield closer to that of the com-
ndency towards a smaller size of invasive lesion at parison centres (RR from 0.81 to 0.89) but does not bring it
was more evident in Nottingham which argues to unity while the crude relative risk for Nottingham (RR
te hypothesis that BSE was responsible for the lower 1.2) remains unaffected.
Table II Women undergoing various treatments for management of newly diagnosed breast
cancers during first 7 years (percentages of breast cancer patients)
Total Breast
breast conserving Endocrine
Centre cancers operationa Chemotherapy therapy Radiotherapy
Huddersfield 289 30.4% 39.4% 53.6% 50.5%
Nottingham 555 13.3% 2.3% 18.0% 16.6%
Comparison centres 1528 19.4% 6.0% 26.4% 41.4%
aIncludes quadrantectomy, lumpectomy, wide excision, tylectomy, and subcutaneous mastectomy.
Table III Breast cancer deaths over 10 years offollow-up and expected deaths (based on the
pooled rates of the six centres)
Expected Expected
Observed Age and period With pre-trial SMR
Centre no. adjusted adjustment
Huddersfield 91 116.4 115.3
Nottingham 232 193.2 206.8
Comparison centres 646 659.3 641.1
Risks relative to the combined comparison centres:
Without pre-trial With pre-trial SMR
adjustment (95% Cl) adjustment (95% Cl)
Huddersfield 0.80 (0.64-0.99) 0.78 (0.61-0.96)
Nottingham 1.23 (1.06-1.43) 1.14 (0.95-1.35)
Combined BSE centres 1.07 (0.93-1.22) 1.01 (0.86-1.17)
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Differences in underlying breast cancer incidence could
also lead to differences in mortality. The adjustment whereby
expected deaths for each district were multiplied by the pre-
trial breast cancer SMRs was intended to counter bias due to
differing underlying incidence rates but may fail to do so
where boundary and demographic changes have occurred. It
may also be relevant that the SMRs are based on all breast
cancer deaths irrespective of the length of survival whereas
the observed deaths in a study with limited follow up are
biased towards exclusion of deaths after late recurrence; a
centre where women traditionally referred themselves early
would have a lower observed mortality in a study such as
ours even though its SMR was 100%.
Trends in breast cancer mortality are shown in Figure 2.
These are for cancers which may have been diagnosed at any
time in the past, whereas trial death rates refer to women
who were apparently disease-free at entry. The trends
confirm that some improvement has occurred in Hud-
dersfield. The improvement was not seen in women over 74
but was as marked in women under 45 as in those who were
in the trial age range. This suggests that if the BSE prog-
ramme is responsible, the benefit may be from its general
effect of increasing breast awareness rather than an effect
restricted to those directly targeted.
During the TEDBC period the results of clinical trials of
mastectomy vs breast conservation were beginning to
influence management (Gazet et al., 1985), and some of the
centres were themselves running further trials. It is unlikely
that differences in extent of surgery shown in Table II would
alter mortality although clearly having a major effect on
morbidity and possibly an effect on early self-referral
behaviour. However, both adjuvant chemotherapy and
tamoxifen are now known to improve survival (Early Breast
Cancer Trialists' Collaborative Group, 1992). On the
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population.
assumption that such therapy reduces mortality of cancers
without local fixation or distant metastasis by about 25% we
can estimate the extent to which equal use of these agents in
all centres might have reduced differences between centres
(Table V). The difference between Nottingham and Hudders-
field is only slightly reduced. We have also looked for bias
affecting ascertainment of breast cancer deaths by reassessing
the cause of death in all breast cancer patients in the trial.
None was found (UK Trial of Early Detection of Breast
Cancer Group, 1991).
These findings reported here are seemingly at variance with
two studies carried out in Nottingham (based on the popula-
tion ofNorth Nottingham in addition to that included in this
trial) which appeared to show a benefit from the BSE pro-
gramme (Locker et al., 1989). They compared prognostic
factors of cases detected after the BSE campaign began with
those in a pre-trial series of cases notified by the local cancer
registry and also used a case-control design to compare the
BSE class attendance of women who died of breast cancer
with that of age-matched controls. Ascertainment of cases
was not, however, as thorough in the pre-trial period as
during the trial and lead time and length biases also make
interpretation difficult. Likewise the case-control method is
prone to selection bias which has been found to exaggerate
the estimate of benefit in studies of mammographic screening
trials (Moss et al., 1992; Gulberg et al., 1991). The case-
control method may also have been biased by the exclusion
from consideration of cancers detected in the first 3 months
after invitation.
We conclude that the favourable mortality in Huddersfield
may be partly due to the programme but it is also influenced
by biases which cannot be corrected for. The difficulties
experienced in trying to evaluate the BSE programmes
naturally raise the question of the validity of inferences about
the screening centres since they were compared with the
same, geographically separate populations. The consistency
of mortality reduction between the two screening centres
(UK Trial of Early Detection of Breast Cancer Group, in
press) and the similarity with results from elsewhere together
with the conformity of the cancer incidence patterns to
theoretical expectations in regard to prevalence/incidence
ratios, size distribution at detection and incidence rates in the
intervals between screens strongly suggest that women in the
screening centres did benefit. The size of benefit cannot how-
ever be accurately estimated in view of the sources of bias
which have been discussed.
Unfortunately the only current BSE trials which might
provide more conclusive evidence, are trials in Moscow, Len-
ingrad and East Berlin (Koroltchouk, 1990) in which fac-
tories are randomised, and these trials are jeopardised by
political upheavals. The suggestion that a BSE programme
with annual, personal, postal reminders may be effective,
especially in societies where late cancer presentation is com-
mon, could be further pursued. A trial based solely on postal
BSE encouragement in Belfast (Turner et al., 1984) showed
some impact on behaviour although it was too small and
Table V Effect of assuming that 25% of deaths occurring in non-advanced cases not given adjuvant therapy
could have been avoided
Deaths among non- Expected deaths
advanced cases not assuming adjuvant
Total deaths given adjuvanta prevents 25%
(n) (per 1000 w.y.) (a) (n - I a) (per 1000 w.y.)
Huddersfield 91 0.424 21 85.75 0.400
Nottingham 232 0.629 96 208 0.564
Comparison centres 646 0.531 200 596 0.490
Expected RR with
use of adjuvant
Crude RR (95% Cl) for all (95% Cl)
Comparison centres 1.00 1.00
Huddersfield 0.80 (0.04-0.99) 0.82 (0.65-1.02)
Nottingham 1.18 (1.02-1.38) 1.15 (0.98-1.35)
aCases without local fixation or distant metastases, not given tamoxifen or chemotherapy.
v' n212 R. ELLMAN et al.
short-lived to show an effect on breast cancer mortality.
Perhaps a larger and more sustained randomised controlled
trial of BSE encouragement, based solely on postal re-
minders, should be attempted in a situation where the cost of
mammographic screening is prohibitive.
This work was funded by the Department of Health but does not
necessarily represent the views of the Department.
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